3.Indication of Drug Therapy in Patients with Chronic Hepatitis B.
The Korean Journal of Hepatology 2005;11(1):1-8
No abstract available.
Hepatitis B, Chronic/*drug therapy
;
Humans
4.Effects of zeffix (lamivudine) in treatment of chronic hepatitis B
Journal of Medical Research 2003;26(6):76-83
The results of the study on 33 cases of chronic hepatitis B treated with Zeffix (100mg = 1 tablet/day, in 2 fears continously) showed that the rate of patients who have normalized level of liver enzyme (AST and ALT) accounted for 66.6%. The sero conversion rate of HBeAg and negatiity of HBV-DNA was 48.5%. 45.5% of patients were recovered and the rate of recurrent was 9%. Zeffix has not side effects (some cases of fever, nausea, vomit of slight manifestation.
therapy
;
Therapeutics
;
drugs
;
Hepatitis B, Chronic
5.Progress in immunotherapy for chronic hepatitis B.
Chinese Journal of Hepatology 2012;20(10):723-725
7.Advances in new antivirals for chronic hepatitis B.
Yanhua TANG ; Hongyan LIANG ; Ge ZENG ; Sheng SHEN ; Jian SUN
Chinese Medical Journal 2022;135(5):571-583
Chronic hepatitis B virus (HBV) infection remains a global health burden. Timely and effective antiviral therapy is beneficial for patients with HBV infection. With existing antiviral drugs, including nucleos(t)ide analogs and interferon-alfa, patients can achieve viral suppression with improved prognosis. However, the rate of hepatitis B surface antigen loss is low. To achieve a functional cure and even complete cure in chronic hepatitis B patients, new antivirals need to be developed. In this review, we summarized the advantages and disadvantages of existing antiviral drugs and focused on new antivirals including direct-acting antiviral drugs and immunotherapeutic approaches.
Antiviral Agents/therapeutic use*
;
Hepatitis B/drug therapy*
;
Hepatitis B Surface Antigens
;
Hepatitis B virus
;
Hepatitis B, Chronic/drug therapy*
;
Hepatitis C, Chronic/drug therapy*
;
Humans
10.The 2014 Hepatology Society of the Philippines consensus statements on the management of chronic hepatitis B.
Jamias Jade D. ; Balce-Santos Dulcinea A. ; Bocobo Joseph C. ; Labio Madalinee Eternity D. ; Lontok Ma. Antoinette DC. ; Macatula Therese C. ; Ong Janus P. ; Ong-Go Arlinking K. ; Wong Stephen ; Yu Ira I. ; Payawal Diana A.
Philippine Journal of Internal Medicine 2015;53(1):17-33
Chorinic hepatitis B virus (CHB) infection is a serious problem that affects over 300 million people worldwide and is highly prevalent in the Asia Pacific region. In the Philippines an estimate 7.3 million Filipinos or 16.7% of adults are chronically infected with HBV, more than twice the average prevalence in the Western Pacific region.
In view of the above, the Hepatology Society of the Philippines (HSP) embarked on the development of consensus statements on the management of hepatitis B with the primary objectives of standardizing approach to management, empowering other physicians involved in the management of hepatitis B and advancing treatment subsidy by the Philippine Health Insurance Corporation (PhilHealth).
The local guidelines include screening and vaccination general management, indications for assessment of fibrosis in those who did not meet treatment criteria. indications for treatment, on-treatment and post-treatment monitoring and duration of antiviral treatment. Recommendations on the management of antiviral drug resistance, management of special populations including patients with concurrent HIV or hepatitis C infection, women of child-bearing age (pregnancy and breastfeeding), patients with decompensated liver disease, patients receiving immunosuppressive medications or chemotherapy and patients in the setting of hepatocellular carcinoma are also included. However, the guidelines did not include management for patients with liver and other solid organ transplantation, patients on renal replacement therapy, and children.
The consensus statements will be amended accordingly as new therapies become available.
Hepatitis B ; Consensus ; Hepatitis B, Chronic ; Hepatitis B Virus ; Fibrosis ; Drug Therapy ; Carcinoma, Hepatocellular ; Liver Cirrhosis ; Hepatitis Delta Virus ; Hiv
Result Analysis
Print
Save
E-mail